Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories medical Devices — Segment Total Assets ($M) ($M)
Postgres DB segment_values + Form 10-K/10-Q Segment Footnote
Latest, Q2 2026
11,406
Period ended Jun 30, 2026
Change on a year earlier
+8.1%
10,555 in Q2 2025
History
14 quarters
Since Q4 2017
Sources
12
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Medical Devices — Segment Total Assets ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 11,406 | +8.1% | Form 10-Q (filed 2026-07-28) ↗ |
| Q1 2026 | Mar 31, 2026 | 10,983 | +9.5% | Form 10-Q (filed 2026-04-29) ↗ |
| Q4 2025 | Dec 31, 2025 | 10,689 | +12.8% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 10,576 | – | Form 10-Q (filed 2025-10-29) ↗ |
| Q2 2025 | Jun 30, 2025 | 10,555 | – | Form 10-Q (filed 2025-07-30) ↗ |
| Q1 2025 | Mar 31, 2025 | 10,034 | – | Form 10-Q (filed 2025-04-30) ↗ |
| Q4 2024 | Dec 31, 2024 | 9,472 | +4.9% | Form 10-K (filed 2025-02-21) ↗ |
| Q4 2023 | Dec 31, 2023 | 9,029 | +15.1% | Form 10-K (filed 2024-02-16) ↗ |
| Q4 2022 | Dec 31, 2022 | 7,844 | +8.0% | Form 10-K (filed 2023-02-17) ↗ |
| Q4 2021 | Dec 31, 2021 | 7,261 | +5.3% | Form 10-K (filed 2022-02-18) ↗ |
| Q4 2020 | Dec 31, 2020 | 6,893 | +3.8% | Form 10-K (filed 2021-02-19) ↗ |
| Q4 2019 | Dec 31, 2019 | 6,640 | +12.8% | Form 10-K (filed 2020-02-21) ↗ |
| Q4 2018 | Dec 31, 2018 | 5,886 | +1.5% | Form 10-K (filed 2020-02-21) ↗ |
| Q4 2017 | Dec 31, 2017 | 5,799 | – | Form 10-K (filed 2020-02-21) ↗ |
Breakdown
What makes up medical devices — segment total assets ($m)
- Diagnostic Products — Segment Total Assets ($M)9,709 · Q2 2026
- Nutritional Products — Segment Total Assets ($M)5,278 · Q2 2026
- Established Pharmaceutical Products — Segment Total Assets ($M)3,819 · Q2 2026
- Medical Devices — Segment Depreciation & Amortization ($M)106 · Q2 2026
- Diagnostic Products — Segment Depreciation & Amortization ($M)165 · Q2 2026
- Nutritional Products — Segment Depreciation & Amortization ($M)51 · Q2 2026
- Established Pharmaceutical Products — Segment Depreciation & Amortization ($M)25 · Q2 2026
Cite this data
StockData. (2026). Abbott Laboratories Medical Devices — Segment Total Assets ($M) ($M), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/db-seg-assets-md
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.